

Author Index (Vol. 18, Suppl. 2)

- Adler, R., see Shouval, D., S32
 Adler, R. and Shouval, D., A finger-stick assay for determination of immunity to hepatitis A: a preliminary report, S27
 Armstrong, M.E., Giesa, P.A., Davide, J.P., Redner, F., Waterbury, J.A., Rhoad, A.E., Keys, R.D., Provost, P.J. and Lewis, J.A., Development of the formalin-inactivated hepatitis A vaccine, VAQTA TM from the live attenuated virus strain CR326F, S20
 Ashur, Y., see Shouval, D., S32
 Bishop, R., see Nalin, D.R., S51
 Bittner, R., see Jilg, W., S38
 Block, S.L., see Nalin, D.R., S51
 Brown, L., see Nalin, D.R., S51
 Brown, L., see Shouval, D., S32
 Brown, L., see Werzberger, A., S46
 Calandra, G.B., see Nalin, D.R., S51
 Carlsson, R.-M., Claesson, B.A. and Iwarson, S.A., Dose response study of an inactivated hepatitis A virus vaccine S41
 Claesson, B.A., see Carlsson, R.-M., S41
 Davide, J.P., see Armstrong, M.E., S20
 Deinhardt, F., see Jilg, W., S38
 Ellerbeck, E., see Nalin, D.R., S51
 Giesa, P.A., see Armstrong, M.E., S20
 Hilleman, M.R., A tribute to Dr. Friedrich W. Deinhardt, MD. 1926-1992, S2
 Hilleman, M.R., Hepatitis and hepatitis A vaccine: a glimpse of history, S5
 Hilleman, M.R., Foreword, S1
 Iwarson, S.A., see Carlsson, R.-M., S41
 Jilg, W., Bittner, R., Schätzl, H., Rasshofer, R., Schmidt, M. and Deinhardt, F., The immune response to different doses of inactivated hepatitis A vaccine, S38
 Keys, R.D., see Armstrong, M.E., S20
 Koval, R., International symposium on hepatitis A vaccine Rhodes, Greece, June 10, 1992. Session I. Rationale for an inactivated hepatitis virus vaccine. Discussion Period Session I, S65
 Kuter, B., see Shouval, D., S32
 Kuter, B., see Werzberger, A., S46
 Kuter, B.J., see Nalin, D.R., S51
 Lemon, S.M., Immunologic approaches to assessing the response to inactivated hepatitis A vaccine, S15
 Lewis, J., see Werzberger, A., S46
 Lewis, J.A., see Armstrong, M.E., S20
 Lewis, J.A., see Nalin, D.R., S51
 Lewis, J.A., see Shouval, D., S32
 Margolis, H.S., see Shapiro, C.N., S11
 Margolis, H.S. and Shapiro, C.N., Considerations for the development of recommendations for the use of hepatitis A vaccine, S56
 Mensch, B., see Werzberger, A., S46
 Miller, W., see Shouval, D., S32
 Miller, W., see Werzberger, A., S46
 Miller, W.J., see Nalin, D.R., S51
 Nalin, D., see Werzberger, A., S46
 Nalin, D.R., Kuter, B.J., Brown, L., Patterson, C., Calandra, G.B., Werzberger, A., Shouval, D., Ellerbeck, E., Block, S.L., Bishop, R., Wiens, B., Schwartz, S.W., Lewis, J.A., Sitrin, R.D., Provost, P.J., Miller, W.J. and Ryan, J.L., Worldwide experience with the CR326F derived inactivated hepatitis A virus vaccine in pediatric and adult populations: An overview, S51
 Nalin, D.R., see Shouval, D., S32
 Patterson, C., see Nalin, D.R., S51
 Provost, P., see Werzberger, A., S46
 Provost, P.J., see Armstrong, M.E., S20
 Provost, P.J., see Nalin, D.R., S51
 Purcell, R.H., Control of hepatitis A by inactivated vaccines: unanswered questions and unresolved issues, S61
 Rasshofer, R., see Jilg, W., S38
 Redner, F., see Armstrong, M.E., S20
 Rhoad, A.E., see Armstrong, M.E., S20
 Ryan, J.L., see Nalin, D.R., S51
 Schätzl, H., see Jilg, W., S38
 Schmidt, M., see Jilg, W., S38
 Schwartz, S.W., see Nalin, D.R., S51
 Shapiro, C.N., Margolis, H.S., Worldwide epidemiology of hepatitis A virus infection, S11
 Shapiro, C.N., see Margolis, H.S., S56
 Shouval, D., Ashur, Y., Adler, R., Lewis, J.A., Miller, W., Kuter, B., Brown, L. and Nalin, D.R., Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin, S32
 Shouval, D., see Adler, R., S27
 Shouval, D., see Nalin, D.R., S51
 Shouval, D., see Werzberger, A., S46
 Sitrin, R., see Werzberger, A., S46
 Sitrin, R.D., see Nalin, D.R., S51
 Waterbury, J.A., see Armstrong, M.E., S20
 Werzberger, A., Kuter, B., Shouval, D., Mensch, B., Brown, L., Wiens, B., Lewis, J., Miller, W., Sitrin, R., Provost, P., and Nalin, D., Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial, S46
 Werzberger, A., see Nalin, D.R., S51
 Wiens, B., see Nalin, D.R., S51
 Wiens, B., see Werzberger, A., S46